TOFWERK’s Post

Exciting news in the field of medicine! Researchers at Weill Cornell Medicine have developed a groundbreaking human neuron model that simulates the spread of tau protein aggregates, a key factor in Alzheimer's disease. This advancement opens new doors for potential therapeutic targets that could halt the progression of this devastating condition. For more details on this innovative research, check out the full article https://lnkd.in/eUm32dzJ

A more than interesting article!

Check out the groundbreaking research on fibrosis and its impact on the cardiac ECM, conducted by Giancarlo Forte's team! This study, using Optics11 Life's high-throughput Pavone technology, provides crucial insights into how fibrosis changes ECM properties to develop innovative treatments for heart disease. 🔬 Key Highlights: ➝ Development of in vitro models that more accurately mimic human cardiac tissue. ➝ Emphasis on the importance of ECM remodeling in understanding heart disease. This research broadens perspectives beyond traditional methods, potentially advancing cardiac health research and treatment. Dive deeper into the study and its implications: https://lnkd.in/diDiWBKB #Cardiachealth #Pavone #Fibrosis

This year marks the 20th anniversary of the Alzheimer's Disease Neuroimaging Initiative (ADNI) study. ADNI is the largest study worldwide, designed to collect detailed longitudinal clinical, neuroimaging, biofluid, genetic and pathologic information from volunteers and make all information available to the scientific community. ADNI has enrolled 2,500 research participants from 60 sites across North America that span the cognitive continuum from normal to dementia with a focus on Alzheimer’s disease. Magnetic Resonance Imaging (MRI) has been one of the components of ADNI from the study inception. The MRI Core of ADNI provides standardized carefully curated MR images that represent the most widely used MR image types and numeric summary values used in modern observational research and clinical trials for Alzheimer's Disease and related disorders. This overview paper describes past and current versions of the #ADNI MRI acquisition and analysis methods which have evolved extensively to remain scientifically current. The paper provides a useful, detailed resource for anyone wishing to use ADNI MRI data: https://bit.ly/4d2yRVO

Is Long COVID still an issue?   Recent data from the Centers for Disease Control and Prevention shows 6.8% of US adults affected, about 17.6 million people. The Symptoms range from brain fog to fatigue. Additionally, Pulmonary Long COVID presents further complications, affecting the lungs and respiratory system even after the initial infection has resolved. Symptoms include shortness of breath, persistent cough, and residual lung damage, significantly limiting day-to-day activities for over three-quarters of those affected. These staggering numbers highlight the urgent need for a deeper understanding. Lung abnormalities are the most common manifestations of Long COVID, and despite the prevalence, there's no clear diagnostic or treatment protocol. As the Polarean recent post represents, our collaborators, in a multicenter 135-patient study, identified four distinct disease characteristics of Long COVID through direct visualization of lung function using the #XenonMRI platform. This promising development holds the potential to help physicians and patients unravel the mysteries of their lung-related Long COVID. Kudos to our collaborators! 🙏👍💪🫁 #longcovidawareness #longcovid #PASC #COVID19

🚀 Revolutionizing Heart Health: Biomimetic Nanomaterials Unleash Healing Power After a Heart Attack! 💔🔬 In a groundbreaking study, Dr. Jason R. McCarthy, a trailblazer in biomedical research and translational medicine, unveils a transformative approach to minimize damage post-heart attack. Published in Advanced Materials, the study "Biomimetic Nanomaterials for the Immunomodulation of the Cardiosplenic Axis Post-Myocardial Infarction" introduces a novel strategy utilizing biomimetic nanomaterials for targeted immunomodulation. 💡 Unlocking the Healing Potential: Targeting the Cardiosplenic Axis McCarthy's research focuses on leveraging biomimetic nanomaterials to target the spleen precisely, a key player in the immune response post-heart attack. By designing nanomaterials that mimic dead red blood cells, the team orchestrates retention in the spleen, enabling the delivery of histone deacetylase (HDAC) inhibitors. These chemical compounds, known for treating various diseases, showcase the potential to enhance the healing response after a heart attack. 🩸 Reducing Scar Size and Preserving Heart Function: A Game-Changing Outcome Remarkably, the targeted delivery of HDAC inhibitors through biomimetic nanomaterials results in a significant decrease in cardiac scar size and the preservation of heart function, even with just one dose administered within two hours of a heart attack. This holds immense promise for minimizing cardiac damage and potentially preventing subsequent events or arrhythmias. 💪 A Potential Paradigm Shift in Cardiac Care With heart disease being the leading cause of death in the U.S., affecting one in five Americans, McCarthy's innovative strategy opens new vistas in cardiac care. The potential clinical application of this approach could substantially reduce cardiac damage, offering hope for improved post-heart attack outcomes. 🔬 Advancing Beyond Cardiac Care: Exploring New Avenues Dr. McCarthy envisions extending the impact of this groundbreaking approach beyond cardiac care. The study's success prompts further exploration of these biomimetic nanomaterials in treating other conditions like lupus and pneumonia, demonstrating the versatility and potential of this pioneering research. Join the journey toward redefining heart health with biomimetic nanomaterials! 🌐💖✨ #MedicalInnovation #HeartAttackRecovery #BiomedicalResearch #NanotechnologyInMedicine #HeartHealth #NanomaterialsInMedicine #MedicalBreakthrough #cardiaccare https://lnkd.in/gfNfr2-w

I’m thrilled to share our recent manuscript published in Nature Communications: "Multisensory gamma stimulation mitigates the effects of demyelination induced by cuprizone in male mice." Our new findings from the Li-Huei Tsai lab suggest that gamma entrainment using sensory stimuli reduces the detrimental effects of cuprizone by mitigating demyelination, promoting oligodendrogenesis, preserving functional integrity and synaptic plasticity, attenuating oligodendrocyte ferroptosis-induced cell death, and reducing brain inflammation. This research opens exciting new possibilities for treating demyelination conditions with non-invasive gamma therapy. A huge thank you to my co-authors, Lorenzo Bozzelli, Thomas Kim, Liwang Liu, Oliver Gibson, Cheng-Yi Yang, Mitchell Murdock, Fabiola Galiana Meléndez, Brooke Schatz, Alexis Davison, Md Rezaul Islam, Dong Shin Park, Ravikiran Raju, Fatema Abdurrob, Alissa Nelson, Jian Min Ren, Vicky Yang, Matt Stokes and Li-Huei Tsai. Special thanks to Li-Huei Tsai and the The Picower Institute for Learning and Memory for making my postdoc experience at Massachusetts Institute of Technology unforgettable! Read the full paper here: https://lnkd.in/dTPiVZRu

Using advanced microscopy techniques that were developed through an NIA and National Institute of Neurological Disorders and Stroke (NINDS) collaboration, NIA funded researchers found that when a signaling pathway called ApoER2-Dab1 malfunctions in human brain neurons, the neurons accumulate phosphorylated tau and die during the earliest stages of Alzheimer's disease. Learn more about the data and why it suggests that the destabilization of the ApoER2-Dab1 pathway is a plausible, alternative explanation for why specific neurons degenerate in Alzheimer’s disease: https://lnkd.in/ehyxic7q #NIAFunded #NIHAging #ApoER2 #Neurons #AlzheimersDisease

Protein folding factors play a key role in neurodegeneration For the first time, researchers have mapped out the proteins implicated in the early stages of motor neurone disease (MND). They have developed a longitudinal map of the proteins involved in MND across the trajectory of the disease, identifying potential therapeutic pathways for further investigation.. “Before the onset of MND in mouse models, we observed a marked increase in protein groups responsible for physically assisting in the protein folding process. “One of these ‘chaperone’ proteins, DNAJB5, was particularly abundant early on, sparking our curiosity about its role in disease progression. “In human brain tissue, we found DNAJB5 enriched in areas where TDP-43 aggregates. “The short-term elevation of DNAJB5 is likely a protective mechanism by neurons in an attempt to control TDP-43 as it begins to dysfunction. DNAJB5 over-expression decreased TDP-43 aggregation in cell and cortical neuron cultures, and knockout of Dnajb5 exacerbated motor impairments caused by AAV-mediated cytoplasmic TDP-43 expression in mice. #ScienceMission #sciencenewshighlights https://lnkd.in/giey7WFm

According to this article from the Mayo Clinic in Medical Xpress, scientists have identified unique molecular signatures indicating dysfunction in the blood-brain barrier in Alzheimer's disease, which could lead to new methods for diagnosing and treating the condition. Led by Dr. Nilufer Ertekin-Taner, the team analyzed brain tissue from Alzheimer's patients and healthy individuals, studying thousands of cells across six brain regions. They focused on pericytes and astrocytes, key cells maintaining the blood-brain barrier, and discovered altered communication between these cells mediated by molecules VEGFA and SMAD3. Their findings suggest that elevated VEGFA levels in Alzheimer's patients reduce SMAD3 levels, impacting vascular health. Using cellular and zebrafish models, the researchers confirmed this relationship, observing decreased SMAD3 levels in brain pericytes treated with VEGFA. Higher blood SMAD3 levels correlated with less vascular damage and better outcomes in Alzheimer's disease. Further research aims to explore SMAD3's role in Alzheimer's progression and identify additional molecules affecting the blood-brain barrier. #AlzheimersResearch #BloodBrainBarrier #MayoClinic #ENDALZ